Ultragenyx Pharmaceutical (NASDAQ:RARE) Downgraded by The Goldman Sachs Group to Neutral

The Goldman Sachs Group lowered shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) from a buy rating to a neutral rating in a research report sent to investors on Tuesday morning, MarketBeat reports. The Goldman Sachs Group currently has $25.00 price objective on the biopharmaceutical company’s stock, down from their prior price objective of $61.00.

A number of other brokerages also recently issued reports on RARE. Leerink Partners cut their price target on shares of Ultragenyx Pharmaceutical from $80.00 to $70.00 and set an “outperform” rating for the company in a report on Tuesday, December 30th. Jefferies Financial Group lowered their price objective on Ultragenyx Pharmaceutical from $114.00 to $63.00 and set a “buy” rating for the company in a research report on Tuesday, December 30th. Bank of America cut their target price on Ultragenyx Pharmaceutical from $72.00 to $58.00 and set a “buy” rating for the company in a research note on Friday, January 2nd. Robert W. Baird reduced their target price on Ultragenyx Pharmaceutical from $72.00 to $47.00 and set an “outperform” rating on the stock in a research report on Tuesday, December 30th. Finally, Barclays decreased their price target on Ultragenyx Pharmaceutical from $81.00 to $50.00 and set an “overweight” rating on the stock in a research note on Monday, November 24th. Fifteen research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Ultragenyx Pharmaceutical currently has a consensus rating of “Moderate Buy” and an average target price of $60.47.

Ultragenyx Pharmaceutical Trading Down 8.7%

Shares of RARE stock opened at $18.50 on Tuesday. Ultragenyx Pharmaceutical has a twelve month low of $18.29 and a twelve month high of $42.37. The stock has a market cap of $1.79 billion, a price-to-earnings ratio of -3.17 and a beta of 0.16. The company’s 50-day moving average price is $22.59 and its 200-day moving average price is $28.29.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its earnings results on Thursday, February 12th. The biopharmaceutical company reported ($1.29) EPS for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.09). The firm had revenue of $207.28 million for the quarter, compared to analysts’ expectations of $199.60 million. Ultragenyx Pharmaceutical had a negative return on equity of 1,024.42% and a negative net margin of 85.54%.Ultragenyx Pharmaceutical’s revenue for the quarter was up 25.5% on a year-over-year basis. During the same period last year, the firm earned ($1.39) earnings per share. As a group, equities research analysts predict that Ultragenyx Pharmaceutical will post -5.18 EPS for the current year.

Insider Activity at Ultragenyx Pharmaceutical

In related news, CAO Theodore Alan Huizenga sold 1,632 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $22.80, for a total value of $37,209.60. Following the completion of the transaction, the chief accounting officer owned 48,670 shares in the company, valued at approximately $1,109,676. The trade was a 3.24% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Eric Crombez sold 7,029 shares of the company’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $22.80, for a total transaction of $160,261.20. Following the sale, the executive vice president directly owned 76,301 shares in the company, valued at approximately $1,739,662.80. The trade was a 8.44% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 104,958 shares of company stock valued at $2,394,858. 5.50% of the stock is owned by company insiders.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Assetmark Inc. increased its position in shares of Ultragenyx Pharmaceutical by 1,706.7% during the third quarter. Assetmark Inc. now owns 1,084 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 1,024 shares during the period. Huntington National Bank boosted its holdings in Ultragenyx Pharmaceutical by 56.2% in the third quarter. Huntington National Bank now owns 1,092 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 393 shares during the period. Danske Bank A S purchased a new position in Ultragenyx Pharmaceutical in the third quarter valued at $39,000. Smartleaf Asset Management LLC grew its stake in Ultragenyx Pharmaceutical by 205.4% during the 3rd quarter. Smartleaf Asset Management LLC now owns 1,738 shares of the biopharmaceutical company’s stock worth $53,000 after purchasing an additional 1,169 shares in the last quarter. Finally, Covestor Ltd increased its holdings in Ultragenyx Pharmaceutical by 26.0% during the 3rd quarter. Covestor Ltd now owns 1,787 shares of the biopharmaceutical company’s stock worth $54,000 after purchasing an additional 369 shares during the period. Hedge funds and other institutional investors own 97.67% of the company’s stock.

Key Stories Impacting Ultragenyx Pharmaceutical

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Neutral Sentiment: Short-interest reports flagged a “large increase” in March but the published figures are 0 shares / NaN with days-to-cover = 0.0 — this appears to be a data/reporting anomaly and is unlikely to be an immediate market driver.
• Negative Sentiment: Goldman Sachs downgraded Ultragenyx from Buy to Neutral and cut its price target from $61 to $25, citing setrusumab data—this removes a major buy-side endorsement and materially reduces analyst-backed upside, increasing selling pressure. Ultragenyx downgraded to neutral at Goldman Sachs on setrusumab data
• Negative Sentiment: Multiple law firms have issued class-action and lead-plaintiff notices covering purchases from Aug 3, 2023–Dec 26, 2025 and are soliciting clients ahead of an April 6, 2026 deadline. The surge of litigation notices increases legal and settlement risk and can depress investor sentiment until the claims are resolved. Representative notices: Rosen Law Firm; Pomerantz LLP; The Gross Law Firm.
  RARE DEADLINE: ROSEN investor counsel notice
  Pomerantz investor alert
  Gross Law Firm shareholder alert

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.